Bernstein raised the firm’s price target on Insulet (PODD) to $375 from $355 and keeps an Outperform rating on the shares. The firm notes that against a backdrop of accelerating pump market growth, Insulet has a strong moat around the winning form factor, and Omnipod 5 is the clear winner in the growing T2D market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls
- Insulet upgraded to Outperform from Peer Perform at Wolfe Research
- Insulet’s Strong Performance and Growth Potential Justifies Buy Rating
- Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings
- Insulet’s Earnings Call Reveals Strong Growth and Expansion